Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Merestinib - Eli Lilly and Company

Drug Profile

Merestinib - Eli Lilly and Company

Alternative Names: LY-2801653

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Dana-Farber Cancer Institute; Eli Lilly and Company; University of Utah
  • Class Amides; Antineoplastics; Dihydropyridines; Pyrazoles; Small molecules
  • Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors; Proto oncogene protein c met inhibitors; ROS1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Biliary cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Acute myeloid leukaemia; Bone metastases; Cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Jan 2018 Phase-I clinical trials in Bone metastases in USA (PO) (NCT03292536)
  • 27 Sep 2017 Eli Lilly and University of Utah plans a phase I trial for Bone metastases (in patients with Breast cancer) (PO) (NCT03292536)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top